~~<i id='F8F9C05B03'><strike id='F8F9C05B03'><tt id='F8F9C05B03'><pre id='F8F9C05B03'></pre></tt></strike></i>~~

Home» knowledge» hotspot

hotspot

author：focus 2025-09-28 09:20:30 Page View：515

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Mirador, a new biotech startup, launches with $400 million
Next article： https://cbu01.alicdn.com/img/ibank/2016/295/680/3380086592_2017543615.220x220xz.jpg

explore

DIEP, the 'gold standard' of breast reconstruction, is under threat

AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

MoonLake credibility takes another hit with mid

MollyFerguson/STATMoonLakeImmunotherapeutics,aSwissbiotech,wasburiedMondayunderanavalancheofitsownda

Supreme Court strikes down use of affirmative action

ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

Excited delirium, Elijah McClain, and emergency physicians

Theterm“exciteddelirium”hasbeenusedforyearsbylawenforcementandotherfirstresponders,includinghealthca